Clicky

Lotus Pharmaceutical Co Ltd(1795)

Description: Lotus Pharmaceutical Co., Ltd. research, develops, manufactures, and sells generic pharmaceutical products in Taiwan, Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system disease. The company also sells and markets a portfolio of over-the-counter medicines. In addition, it engages in wholesale of cosmetics; retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan. Lotus Pharmaceutical Co., Ltd. is a subsidiary of Alvogen Emerging Markets Holdings Limited.


Keywords: Pharmaceutical Consultancy Services Health Management Health Technology Pharmaceutical Industry In India Sun Pharmaceutical Central Nervous System Disease Business Information Services Generic Pharmaceutical Products Medicinal Chemical

Home Page: www.lotuspharm.com.tw

No. 277 Song Ren Road
Taipei, 110
Taiwan
Phone: 886 2 2700 5908


Officers

Name Title
Mr. Petar Antonov Vazharov GM & Director
Mr. Zenon Zdunek VP of Supply Chain & Operations
Mr. Bjartur Shen VP / Deputy Gen. Mang. of Strategy & Fin.
Ms. Eeling Chan Chief Financial Officer
Angela Luan Corp. Fin. & Regional Investor Relations Director
Ms. Hsieh Gwen Chief Information Officer
Dr. Saral Thangam Chief Exec. Officer of Norwich Clicial Services
Mr. Stanley Gu Country Mang.
Mr. Yao Le Hong VP
Mr. Charles Lin Strategic Consultant

Exchange: TW

Country: TW : Taiwan

Currency: New Taiwan Dollar (NT$)

Forward PE: 0
Trailing PE: 19.3929
Price-to-Book MRQ: 4.9709
Price-to-Sales TTM: 4.3079
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks